Zurich, Jan 18, 2026, 17:32 CET — Market closed
- Roche (ROG) ended the session up 0.93%, closing at 348.90 Swiss francs
- Goldman Sachs upgraded Roche to Neutral, while UBS maintained its Buy rating and raised the target price
- Investors will focus on Roche’s full-year results, due Jan. 29
Roche Holding Ltd’s non-voting shares ended Friday up 0.93%, closing at 348.90 Swiss francs. The stock has remained within a narrow band heading into Monday’s session.
Goldman Sachs upgraded Roche from “sell” to “neutral” and boosted its 12-month price target to 365 Swiss francs, up from 260. The bank highlighted a smoother slate of clinical milestones expected in 2026, following late-2025 trial results. It singled out fenebrutinib, Roche’s experimental multiple sclerosis treatment, and the breast cancer drug giredestrant as key growth drivers. Despite the optimism, Goldman Sachs held back on a buy rating, noting Roche’s sharp rally since November. Investing.com
UBS stayed on the bullish side. Analyst Matthew Weston maintained his buy rating and bumped the target price up to 384 Swiss francs from 356, ahead of Roche’s full-year results due Jan. 29.
Price moves are leading the conversation. Roche last traded at 348.90 Swiss francs, slightly up from a previous close of 345.70. The intraday range stretched from 345.80 to 349.70, matching the high end of its 52-week span between 231.90 and 349.70, per .
A “price target” reflects a broker’s forecast of where a stock might land within the next 12 months. In pharma, “catalysts” usually refer to key events like late-stage trial results, regulatory rulings, or earnings updates that can shift the stock’s trajectory.
Roche’s equity setup adds layers to its ticker. It trades bearer shares and non-voting equity on the SIX Swiss Exchange, while its American depositary receipt appears on the OTCQX market under RHHBY, according to the company’s investor details.
The clinical narrative driving the broker shift has been unfolding for weeks. Back in December, Roche reported that giredestrant reduced the risk of invasive disease recurrence or death by 30% in its phase III lidERA trial. Chief Medical Officer Levi Garraway described the results as evidence of the drug’s potential to become a new standard-of-care endocrine therapy.
That said, the stock’s proximity to its 52-week high means any slip-up—whether slower guidance, messy earnings, or setbacks in late-stage trials—could trigger quick profit-taking.
Looking ahead to the week, the key question is whether Monday’s session will see follow-through buying after recent upgrades or a breather after a solid rally. Traders will also watch broader risk appetite closely, as large-cap pharma often acts as a defensive haven—until it suddenly doesn’t.
Roche’s full-year results drop Thursday, Jan. 29. Investors want to see 2026 guidance and fresh details on the pipeline behind the recent change in broker sentiment.
